IPRIVASK
LOE ApproachingBLASUBCUTANEOUSINJECTABLE
Approved
Apr 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IPRIVASK is a subcutaneous injectable biologic approved in 2003 by Bausch + Lomb. The specific indication and mechanism of action are not publicly documented in available data. This product represents a legacy biologic asset approaching loss of exclusivity.
LOE Approaching
This asset is in late-stage lifecycle with moderate competitive pressure (30/100), indicating a contracting commercial footprint and likely smaller field team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect this product's late-lifecycle status with minimal hiring. Roles available would focus on defending market share and managing LOE transition. Career opportunities are limited; this position would be better for specialists seeking stability rather than growth.
Brand ManagerField Sales Representative
Worked on IPRIVASK at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.